Posts Tagged ‘Josep M. Gatell’

Thursday November 10th, 2016

Scientists from the European AIDS Vaccine Initiative (EAVI2020) meet in Barcelona to analyze the results of the first year of the consortium

Scientists from 22 institutions in Europe, Australia, Canada and the United States meet in Barcelona on November 10-11 to discuss the trajectory and progress of the European AIDS Vaccine Initiative (EAVI2020). This initiative, funded by the European Commission with 23 million euro, started a year ago to accelerate the development of an effective vaccine against HIV. The three Spanish centers participating in the consortium are the IrsiCaixa AIDS Research Institute, which organizes the meeting in Barcelona, the IDIBAPS and the Institute of Health Carlos III. The participation of IrsiCaixa and IDIBAPS is part of HIVACAT, the Catalan research project for an AIDS vaccine.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Tuesday February 02nd, 2016

IDIBAPS takes part in a 30 million euros project to develop new HIV vaccines

IDIBAPS takes part in the European HIV Vaccine Alliance (EHVA) to develop and evaluate new preventive and therapeutic vaccines. The European Commission grants with over 22 million euros in addition to the 6 million euros from Swiss Government. This effort is part of the European Commission Framework Programme for Research and Innovation (Horizon2020) and gathers together HIV leading scientists from 39 public institutions along with European, North American and African companies. Dr. Josep M. Gatell, head of the Infectious Diseases and AIDS IDIBAPS team, is the coordinator from this centre, and Drs. Felipe García, Montserrat Plana and Eloisa Yuste, researchers from the same group, also would join the project. The Spanish National Centre for Biotechnology of the CSIC (CNB-CSIC) also participates.

Read the rest of this entry »

Comments Closed
Tuesday January 12th, 2016

Aelix Therapeutics gets €11.5M for therapeutic HIV vaccine

Aelix Therapeutics, a drug development company created from the HIVACAT project and specialized in the discovery and development of immunotherapies against HIV infection, has completed a funding round of €11.5 M. Ysios Capital, a Spanish investment fund, led the round. The fundraising was also supported by a syndicate of new investors including Johnson & Johnson Innovation – JJDC Inc. (“JJDC”), and Caixa Capital Risc, the venture capital division of Spain’s leading financial group, ‘la Caixa’. Doctors Josep M. Gatell, head of the Infectious Diseases Department at Hospital Clínic and IDIBAPS, Bonaventura Clotet and Christian Brander, from the Institute for AIDS Research (IrsiCaixa), and Jordi Naval, are co-founders of the company and in charge of this project.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Monday November 02nd, 2015

IDIBAPS and IrsiCaixa participate in a 23 million euro project to develop HIV vaccine

IDIBAPS and the IrsiCaixa AIDS Research Institute participate in the European AIDS Vaccine Initiative (EAVI2020), a project to to accelerate the search for an effective HIV vaccine. This initiative, that is part of the European Comission framework programme for research and innovation (Horizon2020), brings together leading HIV researchers from public organisations and biotech companies from across Europe, Australia, Canada and the USA. IrsiCaixa and IDIBAPS are members of this consortium in which participate 22 institutions. Dr. Joan Joseph, researcher at the Infectious Diseases and AIDS IDIBAPS team led by Dr. Josep M. Gatell, will coordinate the project conducted at IDIBAPS over the next 5 years. At IrsiCaixa, an institute led by Dr. Bonaventura Clotet, this project will be coordinated by Dr. Christian Brander, head of the Host Cellullar and Genetic Immunity group and member of the consortium’s steering comitee. The other spanish participant in the consortium is the Instituto de Salud Carlos III.

Read the rest of this entry »

Comments Closed
Friday June 12th, 2015

Hospital Clinic will coordinate the validation of an european ‘app’ to better monitor HIV patients

Researchers from the Hospital Clinic of Barcelona participate in the development and subsequent validation of an application for mobile devices that will facilitate monitoring of HIV patients and the doctor-patient communication. In the European project EmERGE, Hospital Clinic will validate the use of a mHealth platform in a study with 4,000 patients across Europe, 1.000 of whom will be participants of this center. The project, launched last May 6th and coordinated by the University of Sussex (UK), is part of Horizon 2020, the European Comission framework programme for research and innovation, it is endowed with a budget of 6 million euros and includes the participation of several European institutions.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Wednesday November 12th, 2014

A study shows that elite controllers have a similar genetic profile to that of HIV-uninfected people

The elite controllers (EC) are those people in whom AIDS does not progress despite being infected with HIV. A study led by the IDIBAPS and published in the PLOS ONE journal focuses on whether these EC have a specific genetic profile, different from other patients with HIV, which allows them to control viremia without the need of antiretroviral therapy. Thus, researchers have identified 23 miRNAs differentially expressed, four of which are over-expressed in EC and people without the disease and another 19 are under-expressed in this population compared to patients with HIV. The study was led by Dr. Mireia Arnedo and Dr. Montserrat Plana, researchers at the IDIBAPS group of Infectious Diseases and AIDS, led by Dr. Josep Maria Gatell. The article’s first author is Dr. Lander Egaña-Gorroño.

Read the rest of this entry »

Comments Closed
Page 1 of 3123